Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000082237 | SCV000114186 | uncertain significance | not provided | 2013-07-11 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000395808 | SCV000814350 | benign | Kleefstra syndrome 1 | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000082237 | SCV001792497 | likely benign | not provided | 2018-10-26 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 28492532) |
Ambry Genetics | RCV002362732 | SCV002623604 | uncertain significance | Inborn genetic diseases | 2018-02-27 | criteria provided, single submitter | clinical testing | The p.E1283A variant (also known as c.3848A>C), located in coding exon 27 of the EHMT1 gene, results from an A to C substitution at nucleotide position 3848. The glutamic acid at codon 1283 is replaced by alanine, an amino acid with dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000395808 | SCV004237831 | likely benign | Kleefstra syndrome 1 | 2023-11-15 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000082237 | SCV004701483 | likely benign | not provided | 2023-12-01 | criteria provided, single submitter | clinical testing | EHMT1: BS1 |